Back to Journals » International Journal of Nanomedicine » Volume 9 » Issue 1

Lipid nanoparticles for topical and transdermal application for alopecia treatment: development, physicochemical characterization, and in vitro release and penetration studies

Authors Gomes MJ, Martins S, Ferreira D, Segundo M, Reis S

Received 22 March 2013

Accepted for publication 24 May 2013

Published 7 March 2014 Volume 2014:9(1) Pages 1231—1242


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Maria João Gomes,1 Susana Martins,2,3 Domingos Ferreira,2 Marcela A Segundo,1 Salette Reis1

1REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, 2Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal; 3Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark

Abstract: Alopecia is a dermatological disorder, commonly known as hair loss, which affects up to half of the Caucasian male population by middle age, and almost all (95%) Caucasian men by old age. Considering that alopecia affects so many people and that there is currently no scientifically proven treatment with few side effects, new drug-delivery systems able to improve alopecia therapy are urgently required. With this purpose in mind, the present study aimed to develop lipid nanoparticles (nanostructured lipid carriers) with the ability to incorporate and deliver anti-alopecia active compounds (minoxidil and finasteride) into the dermis and hair follicles. Lipid nanoparticles, prepared by ultrasonication method, showed mean particle sizes around 200 nm, which is sufficient for reaching the dermis and hair follicles, and zeta potential values around -30 mV, which indicates good physical stability. Over 28 days of storage, no significant variations in these parameters were observed, which indicates that all nanoformulations are stable in storage over that period. Cryo-scanning electron microscope measurements showed that all the lipid nanoparticles exhibited a spherical shape and a smooth surface regardless of their composition. Differential scanning calorimetry studies allowed the determination of phase transition temperatures and confirmed the recrystallization of the lipid nanoparticles (recrystallization index between 11% and 86%). A high loading efficiency was achieved for finasteride (between 70% and 90%), while less than 30% was achieved for minoxidil nanoparticles, over 28 days. Controlled release assays in physiological conditions demonstrated that nanoparticles loaded with minoxidil yielded a prolonged release, as desired. Penetration assays through pig ear skin demonstrated that nanoparticles loaded with minoxidil and finasteride had low levels of penetration. These results suggest that the proposed novel formulation presents several good characteristics indicating their suitability for dermal delivery of anti-alopecia active compounds.

Keywords: nanostructured lipid carriers (NLC), alopecia, anti-alopecia therapy, minoxidil, finasteride

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Co-association of methotrexate and SPIONs into anti-CD64 antibody-conjugated PLGA nanoparticles for theranostic application

Moura CC, Segundo MA, das Neves J, Reis S, Sarmento B

International Journal of Nanomedicine 2014, 9:4911-4922

Published Date: 23 October 2014

Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability

Neves AR, Lúcio M, Martins S, Lima JL, Reis S

International Journal of Nanomedicine 2013, 8:177-187

Published Date: 7 January 2013

Readers of this article also read:

A stewardship intervention program for safe medication management and use of antidiabetic drugs

Zhao RY, He XW, Shan YM, Zhu LL, Zhou Q

Clinical Interventions in Aging 2015, 10:1201-1212

Published Date: 23 July 2015

Activation of mTOR: a culprit of Alzheimer’s disease?

Cai Z, Chen G, He W, Xiao M, Yan LJ

Neuropsychiatric Disease and Treatment 2015, 11:1015-1030

Published Date: 9 April 2015

Stability and toxicity of empty or gene-loaded lipopolysaccharide-amine nanopolymersomes

Wang QM, Chen Y, Wang LC, Zhang XC, Huang HZ, Teng W

International Journal of Nanomedicine 2015, 10:597-608

Published Date: 13 January 2015

Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics

Adam UU, Husain N, Haddad PM, Munshi T, Tariq F, Naeem F, Chaudhry IB

Neuropsychiatric Disease and Treatment 2014, 10:1953-1959

Published Date: 14 October 2014

Erratum - Intracellular heavy metal nanoparticle storage

Iannitti T, Capone S, Gatti A, et al

International Journal of Nanomedicine 2011, 6:239-240

Published Date: 26 January 2011